一分钟看懂
这是一项关于小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括BMS-986525；Pumitamig，当前状态为招募中。登记地点显示中国北京、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
BMS-986525；Pumitamig · I 期 / II 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Local Institution - 0029 · 北京
- Shanghai East Hospital · 上海
公开的入选条件
- * Participants must have histologically or cytologically documented relapsed/refractory small cell lung cancer (R/R-SCLC).
- * Participants must have received at least 1 platinum-based chemotherapy regimen as per locally approved drug labels and institutional guidelines.
- * In countries where standard of care first line systemic treatment includes platinum containing chemotherapy in combination with anti-PD-(L)1 therapy, it is required that participants have progressed on, are ineligible for or not have access to an anti-PD- (L
- Exclusion Criteria
- * Participants must not have any untreated CNS metastases.
- * Participants must not have an active, known or suspected autoimmune disease.
- * Participants must not have had a prior organ or tissue allograft.
- * Other protocol-defined Inclusion/Exclusion criteria apply.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07325136；登记信息更新于 2026-09-14。